Company Filing History:
Years Active: 1994-1997
Title: The Innovations of Marcel Karl Eberle
Introduction
Marcel Karl Eberle, an accomplished inventor based in Riehen, Switzerland, has made significant contributions to the field of pharmacology with his innovative work. With a portfolio of two patents, Eberle's inventions focus on critical advancements in immunosuppressive therapies.
Latest Patents
Eberle's latest patents highlight his exploration into O-acylated cyclosporins. The first patent involves a cyclosporin formula wherein A is a residue that can take various structural forms, including alkyl, alkoxy, and amino derivatives, ultimately leading to new hydroxy-substituted cyclosporin variants. His second patent encompasses hydroxy-substituted [(D)Ser].sup.8-ciclosporin derivatives, such as [O-(2-hydroxyethyl)(D)Ser].sup.8-ciclosporin, which present advantageous pharmacological properties. These innovations are particularly relevant for the treatment of transplant rejection and autoimmune diseases.
Career Highlights
Marcel Karl Eberle currently works at Sandoz GmbH, a global leader in generic pharmaceuticals and biosimilars. His career at Sandoz has allowed him to engage in cutting-edge research and development, contributing to the advancement of immunology through his innovative patents.
Collaborations
Eberle's work is further enriched through collaborations with his coworkers, including Johann Jakob Boelsterli and Reto Naef. Together, they foster a creative environment that promotes scientific discovery and the successful application of their research findings in the pharmaceutical industry.
Conclusion
Marcel Karl Eberle exemplifies the spirit of innovation within the pharmaceutical sciences. His contributions, particularly in the area of immunosuppressive therapies, underscore his role as a key player in the field, paving the way for new treatment options that improve patient care and outcomes.